Isofol Medical AB (publ) announced that it entered into a license agreement with Solasia Pharma K.K ("Solasia") to develop and commercialize Isofol's proprietary late-stage drug candidate arfolitixorin in Japan. Under the terms of the agreement, Isofol will receive a total amount of ~$ 100 million (SEK 890 million) as upfront, development, regulatory and sales-based milestone payments and clinical development cost. In addition, Isofol will receive tiered royalties on net sales in solid double digit figures. The license agreement is initially focused on the development and commercialization of arfolitixorin as first-line treatment for metastatic colorectal cancer (mCRC) patients in Japan, which is projected to be the second large addressable patient market for arfolitixorin. Additional indications will be evaluated jointly by Solasia and Isofol. Isofol retains rights to arfolitixorin in the rest of the world. Isofol will remain as global sponsor of the AGENT study and Solasia will supervise clinical development activities in Japan and be responsible for registrational filing, and following potential regulatory approvals, Solasia will, as the Market Authorization holder, be responsible for the commercialization of arfolitixorin in Japan. Furthermore, Solasia will pay solid double digit tiered royalty rates on future net sales applicable for the deal. Setterwalls adviced Isofol Medical AB (publ) when entering into a license agreement with Solasia Pharma K.K.